Comparison of levels of antiretroviral drugs with efficacy in children with HIV infection

被引:1
作者
Pilar Nso, Ana [1 ]
Larru, Beatriz [2 ]
Bellon, Jose Ma [2 ]
Jose Mellado, Ma [3 ]
Tomas Ramos, Jose [4 ]
Isabel Gonzalez, Ma [3 ]
Luisa Navarro, Maria [5 ]
Angeles Munoz-Fernandez, Maria [2 ,6 ]
Isabel de Jose, Maria [1 ]
机构
[1] Hosp Univ La Paz, Serv Pediat Infecciosas, Madrid, Spain
[2] Hosp Gen Univ, Lab Inmunobiol Mol, Madrid, Spain
[3] Univ Hosp, Serv Pediat Infecciosas, Madrid, Spain
[4] Hosp Getafe, Serv Pediat Infecciosas, Madrid, Spain
[5] Hosp Gen Univ Gregorio Maranon, Serv Pediat Infecciosas, Madrid, Spain
[6] Unidad Asociada Retrovirol Humana HGUGM CSIC, Madrid, Spain
关键词
Therapeutic drug monitoring; Antiretroviral levels; Children; HIV; PROTEASE INHIBITORS; PLASMA-LEVELS; THERAPY; PHARMACOKINETICS; NELFINAVIR; INDINAVIR; FAILURE;
D O I
10.1007/s12098-010-0052-y
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
To determine the prevelance of low and high antiretroviral (ARV) plasma levels and to analyze correlation between ARV concentrations and the appearance of therapeutic failure and toxicity. The authors present here a study evaluating antiretroviral plasma concentrations in HIV infected children on nonnucleoside reverse transcriptase inhibitors and protease inhibitors based therapy. The authors carried out a multicentre, cross-sectional study, including HIV-infected children from five large Hospitals in Madrid, Spain. Clinical, haematological, biochemical and immuno-virological parameters were assessed. Antiretroviral plasma trough levels were performed using a validated high performance liquid chromatography method. Between April 2006 and April 2008, 129 children were enrolled in the present study, with median treatment duration of 39.2 months. 25.5% of the non-nucleoside reverse transcriptase inhibitors levels were low and 17.6%, high. 27.9% percent of the protease inhibitors levels were low and 12.5%, high. A correlation was found among adequate or high levels of antiretrovirals and normal CD4 percentage and low viral load. Lopinavir/ritonavir plasma levels were correlated with an increase in lipodystrophy. Patients with Tanner stage 1 presented the lowest ARV plasma levels. Full adherence was reported for all the participants by a questionnaire. Many HIV-infected children show ARV plasma levels out of the therapeutic range which demands a child-adjusted approach. However, larger studies are urgently needed in pediatric populations to define optimal reference values.
引用
收藏
页码:397 / 402
页数:6
相关论文
共 23 条
[1]  
[Anonymous], 2008, Guidelines for the use of antirretriviral agents in HIV-1 infected adults and adolescents
[2]   Therapeutic drug monitoring in HIV infection: current status and future directions [J].
Back, D ;
Gatti, G ;
Fletcher, C ;
Garaffo, R ;
Haubrich, R ;
Hoetelmans, R ;
Kurowski, M ;
Luber, A ;
Merry, C ;
Perno, CF .
AIDS, 2002, 16 :S5-S37
[3]   Highly active antiretroviral-treated HIV-infected children show fat distribution changes even in absence of lipodystrophy [J].
Brambilla, P ;
Bricalli, D ;
Sala, N ;
Renzetti, F ;
Manzoni, P ;
Vanzulli, A ;
Chiumello, G ;
di Natale, B ;
Viganò, A .
AIDS, 2001, 15 (18) :2415-2422
[4]  
Cheseaux JJ, 2002, J ACQ IMMUN DEF SYND, V30, P288, DOI 10.1097/00126334-200207010-00004
[5]   Population pharmacokinetics and pharmacodynamics of nelfinavir and its active metabolite M8 in HIV-1-infected children [J].
Crommentuyn, Kristel M. L. ;
Scherpbier, Henriette J. ;
Kuijpers, Taco W. ;
Mathot, Ron A. A. ;
Huitema, Alwin D. R. ;
Beijnen, Jos H. .
PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2006, 25 (06) :538-543
[6]   Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy [J].
Descamps, D ;
Flandre, P ;
Calvez, V ;
Peytavin, G ;
Meiffredy, V ;
Collin, G ;
Delaugerre, C ;
Robert-Delmas, S ;
Bazin, B ;
Aboulker, JP ;
Pialoux, G ;
Raffi, F ;
Brun-Vézinet, F .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2000, 283 (02) :205-211
[7]   Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic-guided therapy: pharmacological data from the Viradapt Study [J].
Durant, J ;
Clevenbergh, P ;
Garraffo, R ;
Halfon, P ;
Icard, S ;
Del Giudice, P ;
Montagne, N ;
Schapiro, JM ;
Dellamonica, P .
AIDS, 2000, 14 (10) :1333-1339
[8]   Pharmacologic characteristics of indinavir, didanosine, and stavudine in human immunodeficiency virus-infected children receiving combination therapy [J].
Fletcher, CV ;
Brundage, RC ;
Remmel, RP ;
Page, LM ;
Weller, D ;
Calles, NR ;
Simon, C ;
Kline, MW .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (04) :1029-1034
[9]   Pharmacokinetics of antiretroviral therapy in HIV-1-infected children [J].
Fraaij, PLA ;
van Kampen, JJA ;
Burger, DM ;
de Groot, R .
CLINICAL PHARMACOKINETICS, 2005, 44 (09) :935-956
[10]   Therapeutic drug monitoring in children with HIV/AIDS [J].
Fraaij, PLA ;
Rakhmanina, N ;
Burger, DM ;
de Groot, R .
THERAPEUTIC DRUG MONITORING, 2004, 26 (02) :122-126